Why Regeneron Pharmaceuticals, Inc. (REGN) stock moved
Regeneron Pharmaceuticals, Inc. (REGN) shares rose 2.4% to $803.29 as of August 10, 2026, a modest gain from the prior close of $784.36. BestStocks flagged the session as a major change for REGN. Below, we break down what changed for REGN, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
REGN climbed 2.4% to $803.29
REGN rose 2.35% to $802.81, buoyed by positive momentum from strong Q2 results and upward earnings revisions. According to the web catalyst synthesis, robust sales of flagship products Dupixent and Eylea HD, combined with Wall Street's steady increase in full-year consensus earnings estimates, have supported the move. An upcoming dividend of $0.94 (ex-date August 18, 2026) and the company's active share buyback program further underpin investor confidence. REGN earnings release scheduled for October 27, 2026 (consensus EPS estimate: $15.29); also monitor the August 18, 2026 dividend ex-date.
What it means for Regeneron Pharmaceuticals, Inc. investors
For Regeneron Pharmaceuticals, Inc. investors, the balance of recent signals points to a bullish shift. On the constructive side: Material positive event; Positive 2.4% session move. Weighing against that: Regeneron Pharmaceuticals, Inc. (REGN) moved -3.56% from $675.19 to $651.18 on 2026-07-22; New SEC filing — review for material disclosures. Wall Street's consensus price target sits at $819.59, implying +2.0% upside from $803.29. Over the past 90 days analysts logged 1 upgrade and 2 downgrades. BestStocks rates the overall signal quality low (40/100). With earnings roughly 79 days out, the next report is the most likely near-term test of the move.
REGN price reaction
REGN last traded at $803.29, up $18.93 (+2.41%) from the previous close of $784.36. The session traded on 0.4× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $651.18 and $803.29, and it currently sits about 100% of the way up that band.
Bullish and bearish analyst opinions on Regeneron Pharmaceuticals, Inc. (REGN)
The consensus analyst price target on Regeneron Pharmaceuticals, Inc. (REGN) is $819.59, 2.0% above the recent $803.29. Over the past 90 days analysts logged 1 upgrade, 19 maintains, and 2 downgrades. Here is how the bullish and bearish cases on REGN line up.
The bullish case
- Wall Street's consensus price target of $819.59 implies +2.0% upside from $803.29.
- The Street's most bullish target is $1,030.00 (+28.2%).
- 1 analyst upgrade in the past 90 days, most recently Benchmark to Buy (2026-07-07).
- Material positive event.
- Positive 2.4% session move.
The bearish case
- The most bearish analyst target is $641.00 (-20.2%).
- 2 analyst downgrades in the past 90 days, most recently Citigroup to Neutral (2026-05-18).
- Regeneron Pharmaceuticals, Inc. (REGN) moved -3.56% from $675.19 to $651.18 on 2026-07-22.
Weighing both sides, BestStocks' composite read of recent signals is bullish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Aug 10, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for REGN
Frequently asked questions about REGN
Why did Regeneron Pharmaceuticals, Inc. (REGN) stock move?
REGN rose 2.4% to $803.29. The move coincided with the context summarized above, though no single company-specific catalyst was independently confirmed.
How much did REGN stock rise?
REGN gained 2.41% ($18.93) versus the prior close of $784.36, last trading at $803.29 on 0.4× average volume.
When is Regeneron Pharmaceuticals, Inc.'s next earnings date?
REGN's next earnings report is estimated for 2026-10-28 — about 79 days away.
What is the analyst price target for REGN?
The consensus analyst price target for REGN is $819.59, about 2.0% above the current $803.29. Over the past 90 days, analysts recorded 1 upgrade, 19 maintains, and 2 downgrades.
How BestStocks tracks REGN
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared REGN-specific materiality thresholds, triggering an evidence check. It draws on 16 tracked change events for REGN, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of August 10, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.